REGENXBIO RGNX 深 滬
等待開盤 08-15 09:30:00 美东时间
9.14
+0.210
+2.35%
華盛通- 最 高9.23
- 今 開8.74
- 成交量 50.73万股
- 最 低 8.58
- 昨 收 8.93
- 總市值 4.61亿
- 52周最高 13.48
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 5.035
- 委 比 95.89%
- 總股本 5038.87万
- 歷史最高 85.10
- 量 比 0.69
- 振 幅 7.28%
- 歷史最低 5.035
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.
08-08 20:10
RegenXBio and AbbVie Amend Collaboration Agreement
RegenXBio ( ($RGNX) ) has shared an update. On August 5, 2025, REGENXBIO Inc. a...
08-07 19:54
Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.10) by 25.8 percent. This is a 31.43 percent decrease over losses of $(1.05) per share from the
08-07 19:06
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
ProKidney Corp.'s Phase 2 REGEN-007 trial for rilparencel in CKD patients with diabetes shows statistically significant improvement in kidney function. Group 1 saw a 78% reduction in eGFR slope decline after two injections, while Group 2 showed a 50% improvement with an exploratory dosing regimen. No serious adverse events were reported. Results will be presented at the American Society of Nephrology 2025 Kidney Week. The FDA Type B meeting in su...
07-08 11:00
REGENXBIO registers 268K shares for resale
REGENXBIO (NASDAQ:RGNX) is registering up to 268,096 shares of common stock for resale by a selling stockholder. Shares are issuable upon exercise of a warrant priced at $14.92, issued in connection w...
06-14 05:34
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.
06-05 23:43
REGENXBIO updates Phase 1/2 data for Duchenne candidate
Disclosing new interim data from its Phase 1/2 AFFINITY DUCHENNE trial, Regenxbio (NASDAQ:RGNX) announced Thursday that its experimental gene therapy RGX-202 continued to benefit patients living with ...
06-05 19:54
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional me...
06-05 19:05
